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progression of a baseline VCF. Each metastatic spinal 
segment was also evaluated according to the six Spinal 
Instability Neoplastic Score (SINS) criteria (location, pain, 
bone lesion type, spinal alignment, posterolateral element 
involvement, bone lesion type, presence of a baseline 
fracture) to evaluate the predictive significance. 
 
Results: The median spine RT total dose, dose per fraction, 
and number of fractions was 30 Gy (range, 8-60 Gy), 3 Gy 
(range, 1.2-18 Gy), and 10 fraction (range, 1-25), 
respectively. The median follow-up for the entire cohort was 
10 months. Nine percent (23/267) had been previously 
irradiated, 8% (20/267) had a baseline VCF, and 47% (83/176) 
were lytic tumor. In all spinal segments, 33 VCF (33/267, 
12%) were observed following RT, including 21 de novo 
fractures and 11 progressive fractures, and the median time 
to VCF was 4 months. The 1-year fracture free probability 
(FFP) was 85%. Multivariate analysis identified sex (p = 
0.005), metastatic involvement (p = 0.012), prior RT (p = 
0.006), and baseline VCF (p < 0.001) as predictors of VCF. 
Among 176 metastatic spinal segments, we observed 32 
fractures (32/176, 18%) with 1-year FFP of 78.1%. 
Multivariate analysis showed that the risk of VCF in 
metastatic spine segments was statistically significant in 
patients with SINS class II/III with or without pre-existing 
baseline VCF (p < 0.001) and prior RT( p < 0.001). 
 
Conclusion: The risk of VCF is higher in women patients with 
a baseline VCF and prior RT. Additionally, in metastatic spine 
segments, the risk of VCF is significant in patients with SINS 
class II/III with or without pre-existing baseline VCF and prior 
RT. SINS criteria can be used as an option for predicting VCF 
risk before performing RT specific to spinal metastases from 
CRC. 
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Purpose or Objective: Metastatic spinal cord compression 
(MSCC) is a common oncological emergency resulting in 
significant morbidity and detrimental functional outcome. 
Population studies suggest an incidence of 3-7% in men with 
metastatic castrate resistant prostate cancer. In our centre, 
therapy monitoring of established bone disease in breast and 
prostate cancer is undertaken with whole body MRI scanning 
(WB-MRI). WB-MRI includes a dedicated spinal examination 
and diffusion weighted sequences that can aid in earlier 
detection of disease progression or response to treatment. 
The aim of this cross-sectional hypothesis generating study 
was to identify if routine WB-MRI reduces the rates of 
symptomatic MSCC in metastatic breast and prostate cancer 
patients. 
 
Material and Methods: Patients with metastatic breast and 
prostate cancer who underwent ≥2 WB -MRI scans between 
2010-2014 were identified and cross-referenced with patients 
receiving emergency radiotherapy for symptomatic MSCC. 
The number of breast & prostate cancer patients, who had ≥2 
WB-MRI scans and received emergency radiotherapy for MSCC 
were recorded.  
 
Results: 63 patients with breast cancer and 89 patients with 
prostate cancer received emergency radiotherapy for MSCC 
between 2010-2014. Of the 365 patients with breast cancer 
who had ≥2 WB -MRI scans, only 1 (0.3%) patient underwent 
emergency radiotherapy for MSCC. 102 patients with 
metastatic prostate cancer had ≥2 WB -MRI scans of which 2 
(2.0%) had emergency radiotherapy for MSCC. 
 
Conclusion: Rates of symptomatic MSCC in this series of 
patients undergoing regular WB-MRI scans for therapy 
monitoring of bone disease are low.  
Routine WB-MRI may aid in the early detection of disease 
progression in the bones, allowing earlier change in systemic 
therapy or the use of prophylactic radiotherapy particularly 
for incipient cord compression. This data generates the 
hypothesis that WB-MRI may prevent progression of bone 
disease and development of symptomatic MSCC. This has the 
caveats that the population studied was selected and in 
particular had relatively stable disease that permitted the 
routine use of WB-MRI. It is possible that the morphological 
spinal MRI examination component, rather than the diffusion 
weighted sequences, may provide much of the utility of the 
WB-MRI examination. Further prospective studies are 
required to confirm our findings. 
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Purpose or Objective: To assess the effectiveness of a SHort-
course Accelerated RadiatiON therapy (SHARON) in the 
palliative treatment of patients with advanced primary or 
metastatic H&N tumors.  
 
Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group performance status of ≤3. Twenty -three patients were 
treated with H&N radiotherapy at 20 Gy (5 Gy per fraction) in 
2 days with a twice daily fractionation. The primary endpoint 
was the assessment of efficacy in terms of symptoms relief. 
 
Results: Characteristics of the enrolled patients were: 
male/female: 9/14; median age: 83 years (range: 40-98). 
Eastern Cooperative Oncology Group performance status was 
<3 in 11 patients (47.8%). Grade 1-2 acute skin (60.9%) and 
mucositis (39.1%) toxicities were recorded. Only one patient 
(4.3%) experienced grade 3 acute mucositis. With a median 
follow-up time of 4 months (range, 1-32 months) 3 skin grade 
1 and 2 skin grade 2 late toxicities have been observed. Of 
the 23 symptomatic patients, 21 showed an improvement or 
resolution of baseline symptoms (overall palliative response 
rate: 91.3%). Three-month overall survival was 89.7% (median 
survival time: N.R.). Median survival without symptoms 
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progression was 5.0 months (95%CI: 1.8-8.1). In 22 patients 
with pain, a significant reduction of this symptom was 
recorded in terms of VAS (mean baseline VAS vs mean VAS at 
follow-up: 4.6 versus 3.1, p<0.001).  
 
Conclusion: Short-course accelerated H&N radiotherapy (20 
Gy in twice daily fractions for 2 consecutive days) is 
tolerated and effective in terms of symptom relief. A phase 
III comparison against a standard palliative regimen (30 Gy in 
10 fractions) has been planned in this patient population. 
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Purpose or Objective: To assess the effectiveness of a SHort-
course Accelerated RadiatiON therapy (SHARON) in the 
palliative treatment of patients with primary or secondary 
thoracic neoplasms, symptomatic, and not susceptible of 
surgery or radical radiotherapy. 
 
Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤3 and an expected 
survival > 3 months. Twenty-five patients were treated with 
radiotherapy (total dose: 20 Gy, 5 Gy per fraction) in 2 days 
with twice daily fractionation. The primary endpoint was to 
evaluate symptoms response rate. 
 
Results: Characteristics of the 25 enrolled patients were: 
male/female: 18/7; median age: 73 years (range: 46-93). 
ECOG performance status was <3 in 24 patients (96%). Two 
G1 skin (8%), 7 G1 haematological (28%) and 4 G1 pulmonary 
(16%) toxicities were recorded. No patient experienced G≥2 
acute toxicities. With a median follow-up time of 6 months 
(range, 1 to 16 months), of the 25 symptomatic patients, 24 
showed an improvement or resolution of baseline symptoms 
(overall palliative response rate: 96%). Three months overall 
survival was 87.5% (median survival time: 6 months; 95% CI 
5.3-6.6 mo). Median survival without symptoms progression 
was 3 months (95% CI:2.2-3.7mo). In 24 patients with pain, a 
significant reduction of this symptom was recorded in terms 
of VAS (5.0 vs 2.9, p=0.02). 
 
Conclusion: Short-course accelerated thorax radiotherapy 
(20 Gy in twice daily fractions, 2 consecutive days) is 
tolerated and effective in terms of symptom relief. A phase 
III comparison against a standard palliative regimen (30 Gy in 
10 fractions) has been planned in this patient population. 
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Purpose or Objective: Modern technologies of radiotherapy 
(SBRT,SABR) are utilized to treat patients with solitary spine 
metastases. Clinical studies have shown the efficacy of 
image-guided SBRT for pain control, local tumor control, as 
well as improvement of the life`s quality for these patients. 
In our clinic we have been using this method since 2013 for 
primary and re-irradiation treatment. 
 
Material and Methods: We have treated 32 pts (20 primary, 
12 reirradiation), 44 lesions. Eligible criteria were ECOG 1-2, 
spine metastases confirmed by MRI, the number of lesions 
were less than 3, adequate control of the primary tumor. 
Mean age 55.8 y.o. (47-72); gender distribution: 12 men and 
20 women. Option of the radiation dose and limit critical 
organs were installed according to the recommendations 
Elekta Spine Radiosurgery Research Consortium (ESRRC) and 
RTOG 0631. The prescribed dose was 12-24 Gy in 1-3 fr. For 
re-irradiation we have used the recommendations of Nieder 
et al.(2006): BED of each course - 98Gy, total BED -135.5Gy, 
the interval between two treatments was more than 6 
months. In these cases the prescribed dose was 20Gy in 5 fr. 
The procedure was performed by VMAT on a linear 
accelerator Elekta Synergy S, equipped with a 4-mm MLC, 
image-guided system (Elekta XVI), 6D robotic positioning 
system table (HexaPod). Overall duration of procedures was 
20-45 min. The follow-up was every 3 months from treatment 
time. It was assessed the pain intensity on a 10-point VAS, 
analgesics, performed MRI control. 
 
Results: Toxicity of SBRT was assessed by using CTC AE 
(v.4.0). Nausea gr.1 was observed in 3 (9.4%) pts, vomiting 
gr.1 - 1 (3.1%) pt. Toxicity gr.3-4 has not been observed. 
There were no cases of therapy interruption due to poor 
tolerability. Hematological toxicity during follow-up period 
was not revealed. In average of the period of 3 weeks all 
patients showed relief of pain syndrome with moderate (4-6 
points) to the minimum (1-3 points). The overall response to 
treatment (decrease of pain syndrome, local tumor control 
by MRI) was 90.6%, including a complete pain relief - 8 (25%) 
pts, stabilization - 21 (65.6%), lack of response to the 
treatment- 3 (9,4%). One patient had a pathological 
compression fracture of the vertebra at 4 months after 
irradiation, which required surgical intervention (installation 
of the fixing system). According to one patient`s MRI after 3 
month of treatment, we have revealed soft tissue component 
of tumor (MRI). 
 
Conclusion: SBRT was well tolerated. We did not observe any 
clinically significant toxicity. Reduction of the overall 
treatment time was comfortable for patients and increase 
capacity of LINAC. Further research is necessary to evaluate 
the efficacy and toxicity of the treatment and the 
development of criteria for the selection of patients. 
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